POSTEXPOSURE PROPHYLAXIS AND TREATMENT OF AEROSOLIZED SMALLPOX
雾化天花的暴露后预防和治疗
基本信息
- 批准号:8173041
- 负责人:
- 金额:$ 6.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-01 至 2011-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAerosolsAnimal ModelAnimalsAntiviral AgentsBiologicalBreathingBypassCidofovirComputer Retrieval of Information on Scientific Projects DatabaseDiseaseDrug FormulationsEvaluationEventExposure toFundingGrantHealth PersonnelHumanInfectionInjectableInstitutionKidneyLifeLungModelingMonkeypoxMonkeysMusOryctolagus cuniculusPharmaceutical PreparationsPowder dose formPoxviridaePoxviridae InfectionsPrimatesProphylactic treatmentRelative (related person)ResearchResearch PersonnelResourcesSafetySelf-AdministeredSmallpoxSmallpox VirusesSourceStructure of parenchyma of lungSyndromeTherapeuticToxic effectUnited States National Institutes of HealthVirusaerosolizedbasedrug inhalationintravenous administrationnonhuman primatepathogenpreclinical efficacy
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Smallpox is a life threatening disease caused by exposure to variola virus, a highly contagious pathogen that is considered a biological threat agent. In the event of an accidental or deliberate aerosol exposure of variola, there are currently no recommended drugs for postexposure prophylaxis and/or treatment for smallpox. Cidofovir is an antiviral drug that can be used to treat infection in the event of a biological attack. An inhaled cidofovir dry-powder formulation is being developed to be used in post-exposure prophylaxis and treatment of aerosol exposure to variola. Inhaled cidofovir has been shown in multiple mouse studies to be highly efficacious against various pox models, producing long-term activity and retention in the lung tissue compared to injectable administration. Intravenous administration of cidofovir, although efficacious, results in lower lung levels, severe kidney toxicity, and requires a health-care worker to implement treatment. Inhalable cidofovir, alternatively, results in high drug levels in the lung, bypasses the kidneys, and is self-administered.
Initially, we will evaluate the inhalable version of cidofovir in a rabbit model of poxvirus infection. Rabbitpox is an ideal animal model for studying poxviruses; it causes a syndrome similar to smallpox in rabbits when the animals are experimentally infected with the virus by aerosol. This antiviral evaluation model will assess if cidofovir effectively inhibits infection in aerosol-exposed rabbits while not causing undue kidney damage or other unwanted adverse effects. Based upon the preliminary results from the rabbitpox studies, we will use an advanced nonhuman primate model of smallpox disease (aerosolized monkeypox in monkeys) to perform efficacy studies to demonstrate that delivery of the antiviral drug by inhalation in the nonhuman primate mirrors that in humans and that such concentrations are positively associated with primate survival when used as a postexposure therapeutic in this lethal model. Results of these studies will establish the relative safety and preclinical efficacy of reformulated cidofovir as a viable antiviral therapeutic against smallpox.
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
天花是一种威胁生命的疾病,由接触天花病毒引起,天花病毒是一种高度传染性的病原体,被认为是一种生物威胁剂。 如果发生意外或故意的天花气雾剂暴露,目前没有推荐的天花暴露后预防和/或治疗药物。 西多福韦是一种抗病毒药物,可用于治疗生物攻击事件中的感染。 正在开发一种吸入西多福韦干粉制剂,用于接触后预防和治疗天花气溶胶暴露。 在多项小鼠研究中,吸入西多福韦已显示出对各种痘模型高度有效,与注射给药相比,在肺组织中产生长期活性和保留。 静脉注射西多福韦虽然有效,但会导致肺部水平降低,严重的肾毒性,需要卫生保健工作者进行治疗。 可吸入的西多福韦,或者,导致在肺中的高药物水平,绕过肾脏,并自我管理。
首先,我们将评估吸入版本的西多福韦在兔痘病毒感染模型。 兔痘是研究痘病毒的理想动物模型;当动物通过气溶胶实验感染病毒时,它会引起与兔天花相似的综合征。 该抗病毒评价模型将评估西多福韦是否有效抑制暴露于气溶胶的兔子的感染,同时不引起过度的肾损伤或其他不必要的不良反应。 基于兔痘研究的初步结果,我们将使用先进的非人灵长类动物天花模型(猴中的雾化猴痘)进行有效性研究,以证明在非人灵长类动物中通过吸入给予抗病毒药物反映了在人类中的情况,并且当在该致死模型中用作暴露后治疗时,此类浓度与灵长类动物存活率呈正相关。 这些研究的结果将建立相对安全性和临床前疗效的西多福韦作为一个可行的抗病毒治疗天花。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHAD J. ROY其他文献
CHAD J. ROY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHAD J. ROY', 18)}}的其他基金
HUMAN ANTIBODIES FOR THERAPEUTIC INTERVENTION OF SEB EXPOSURE
用于 SEB 暴露治疗干预的人类抗体
- 批准号:
8358109 - 财政年份:2011
- 资助金额:
$ 6.18万 - 项目类别:
CONTINUED DEVELOPMENT OF RIVAX VACCINE FOR RICIN
RIVAX 蓖麻毒素疫苗的持续开发
- 批准号:
8358110 - 财政年份:2011
- 资助金额:
$ 6.18万 - 项目类别:
POSTEXPOSURE PROPHYLAXIS AND TREATMENT OF AEROSOLIZED SMALLPOX
雾化天花的暴露后预防和治疗
- 批准号:
8358129 - 财政年份:2011
- 资助金额:
$ 6.18万 - 项目类别:
A NONHUMAN PRIMATE MODEL OF RICKETTSIA PROWAZEKII INFECTION (EPIDEMIC TYPHUS)
普瓦泽克立克次体感染(流行性斑疹伤寒)的非人类灵长类动物模型
- 批准号:
8173017 - 财政年份:2010
- 资助金额:
$ 6.18万 - 项目类别:
HUMAN ANTIBODIES FOR THERAPEUTIC INTERVENTION OF SEB EXPOSURE
用于 SEB 暴露治疗干预的人类抗体
- 批准号:
8173018 - 财政年份:2010
- 资助金额:
$ 6.18万 - 项目类别:
相似海外基金
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
- 批准号:
10092043 - 财政年份:2024
- 资助金额:
$ 6.18万 - 项目类别:
EU-Funded
Molecular-level Understanding Of Atmospheric Aerosols (MUOAA 2024); Corsica, France; April 1-5, 2024
对大气气溶胶的分子水平理解(MUOAA 2024);
- 批准号:
2332007 - 财政年份:2024
- 资助金额:
$ 6.18万 - 项目类别:
Standard Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000021/1 - 财政年份:2024
- 资助金额:
$ 6.18万 - 项目类别:
Research Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000358/1 - 财政年份:2024
- 资助金额:
$ 6.18万 - 项目类别:
Research Grant
Southern Ocean aerosols: sources, sinks and impact on cloud properties
南大洋气溶胶:来源、汇以及对云特性的影响
- 批准号:
DP240100389 - 财政年份:2024
- 资助金额:
$ 6.18万 - 项目类别:
Discovery Projects
INvestigating Home water and Aerosols' Links to opportunistic pathogen Exposure (INHALE): do consumer decisions impact pathogen exposure and virulence?
调查家庭用水和气溶胶与机会性病原体暴露(吸入)的联系:消费者的决定是否会影响病原体暴露和毒力?
- 批准号:
2326096 - 财政年份:2023
- 资助金额:
$ 6.18万 - 项目类别:
Standard Grant
An AI-driven clinical washbasin unit that automatically disinfects pathogens, reduces aerosols and decreases healthcare-acquired infections by 70%
%20人工智能驱动%20临床%20洗脸盆%20单位%20%20自动%20消毒%20病原体,%20减少%20气溶胶%20和%20减少%20医疗保健获得性%20感染%20by%2070%
- 批准号:
83001507 - 财政年份:2023
- 资助金额:
$ 6.18万 - 项目类别:
Innovation Loans
Cloudbusting with JWST: characterising aerosols, aurorae and chemistry in substellar atmospheresto the water cloud regime
使用 JWST 进行云消除:描述水云状态下恒星大气中的气溶胶、极光和化学成分
- 批准号:
ST/X001091/1 - 财政年份:2023
- 资助金额:
$ 6.18万 - 项目类别:
Research Grant
Bioactivated Aerosols for Combustion Product Capture
用于燃烧产物捕获的生物活性气溶胶
- 批准号:
10080253 - 财政年份:2023
- 资助金额:
$ 6.18万 - 项目类别:
Small Business Research Initiative














{{item.name}}会员




